SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company founded in 1999 and headquartered in Redwood City, California. Originally incorporated as Capnia, Inc., the company changed its name to Soleno Therapeutics in May 2017 to reflect its strategic pivot toward developing treatments for rare diseases. After years of clinical development, Soleno achieved a major milestone in 2025 when the FDA approved its lead drug candidate, <b>VYKAT XR</b>, making it the first and only FDA-approved treatment for hyperphagia (excessive hunger) in patients with Prader-Willi Syndrome aged 4 years and older.